A Phase 1, Open-label, Randomized, Crossover Study to Assess the Safety, Tolerability, and Efficacy of CLP With and Without Spironolactone in Adults With Heart Failure

Trial Profile

A Phase 1, Open-label, Randomized, Crossover Study to Assess the Safety, Tolerability, and Efficacy of CLP With and Without Spironolactone in Adults With Heart Failure

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2013

At a glance

  • Drugs Talinexomer (Primary) ; Spironolactone
  • Indications Heart failure
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Mar 2013 Results presented at the 62nd Annual Scientific Session of the American College of Cardiology.
    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jul 2012 Actual initiation date changed from May 2012 to Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top